Clinical Trial Update: This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD). [Phase 2]

View source ↗

Summary

This update reports the termination of a Phase 2 trial evaluating the safety, tolerability, and efficacy of ANB032 in adults with moderate-to-severe Atopic Derm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• ANB032

Snippet

Sponsor: AnaptysBio, Inc. | Conditions: Atopic Dermatitis Eczema | Phase 2 | Status: TERMINATED